<DOC>
	<DOCNO>NCT01452802</DOCNO>
	<brief_summary>The purpose study evaluate compare effectiveness HeartMate II ( HM II ) Left Ventricular Assist Device ( LVAD ) support versus OMM ambulatory NYHA Class IIIB/IV heart failure patient dependent intravenous inotropic support meet FDA approve indication HM II LVAD destination therapy .</brief_summary>
	<brief_title>Risk Assessment Comparative Effectiveness Left Ventricular Assist Device ( LVAD ) Medical Management</brief_title>
	<detailed_description>The HeartMate II ( HM II ) LVAD approve U.S. Food Drug Administration ( FDA ) use destination therapy ( DT ) patient New York Heart Association ( NYHA ) Class IIIB/IV symptom . The ROADMAP trial prospective , multi-center , non-randomized , control , observational study design evaluate effectiveness HM II LVAD support versus optimal medical management ( OMM ) ambulatory NYHA Class IIIB/IV heart failure patient dependent intravenous inotropic support meet FDA approve indication HM II LVAD destination therapy . Subjects enrol one two cohort : OMM LVAD . Together investigator , subject decide cohort enter baseline visit . This study include experience HM II LVAD implant center well community center care large volume heart failure patient . Study patient follow 24 month post enrollment survival , quality life functional status .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>The follow general criterion ; specific criterion include study protocol : NYHA Class IIIB/IV ( refer Appendix IV definition ) Left ventricular ejection fraction ( LVEF ) â‰¤ 25 % Not currently list heart transplantation , plan next 12 month On optimal medical management Limited functional status demonstrate 6MWT &lt; 300 meter At least : One hospitalization HF last 12 month At least 2 unscheduled emergency room infusion clinic visit ( may include intravenous diuretic therapy , etc . ) HF last 12 month Presence mechanical aortic mitral valve , include plan conversion bioprosthesis Platelet count &lt; 100,000/mi within 48 prior enrollment Any inotrope use within 30 day prior enrollment Inability perform 6MWT reason Any condition , heart failure , could limit survival less 2 year History cardiac organ transplant Existence ongoing mechanical circulatory support ( include intraaortic balloon pump , temporary circulatory support device , etc . ) time enrollment Presence active , uncontrolled , systemic infection History unresolved stroke within 90 day prior enrollment , history cerebral vascular disease significant ( &gt; 80 % ) extracranial stenosis Contraindication anticoagulation/antiplatelet therapy CRT CRTD within 3 month prior enrollment Coronary revascularization ( e.g . CABG , PCI ) within 3 month prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HeartMate II</keyword>
	<keyword>heart-assist device</keyword>
	<keyword>medical management</keyword>
	<keyword>optimal medical management</keyword>
	<keyword>Heart Failure NYHA Class IIIB/IV</keyword>
	<keyword>Thoratec Corporation</keyword>
</DOC>